After a long wait, Renalytix AI plc was finally granted de novo authorization from the US Food and Drug Administration for its AI-powered prognostic blood test, KidneyIntelX.dkd, which identifies early-stage kidney disease and guides the management of people with type 2 diabetes.
KidneyIntelX
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?